NCT06369285

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2024-11-19Est. Completion: 2027-12-30

Enrollment target: 225 participants

Locations

Alabama Oncology, Birmingham, Alabama, United States
Mayo Clinic Hospital, Phoenix, Arizona, United States
Beverly Hills Cancer Center, Beverly Hills, California, United States
MemorialCare Orange Coast Medical Center, Fountain Valley, California, United States
City of Hope at Orange County Lennar Foundation Cancer Center, Irvine, California, United States
LA Cancer Network, Los Angeles, California, United States
UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
University of Colorado School of Medicine, Aurora, Colorado, United States
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Mayo Clinic Florida, Jacksonville, Florida, United States
Cancer Specialists of North Florida, Jacksonville, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

Invasive Breast Cancer

This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis o…

Milwaukee, United StatesEst. completion Aug 11, 2025

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms

Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer…

Gilbert, United StatesEst. completion Mar 23, 2033

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.